Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. [PDF]
, 2009 Contains fulltext : 80544.pdf (publisher's version ) (Closed ...
Choy, E. +11 more
core +1 more source
Arthritis care & research, 2019 Multiple studies have shown seemingly unfavorable changes in lipid profiles associated with interleukin‐6 receptor (IL‐6R) antagonists and some other therapies for rheumatoid arthritis.
F. Xie +4 more
semanticscholar +1 more source
Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis
Журнал инфектологииThe presented review searched for articles in the databases PubMed, Web of Science, Scopus, Google Scholar, eLibrary (2002-2022) and assessed the immunogenicity of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in adult patients with ...
B. Ts. Batozhargalova +6 more
doaj +1 more source
Health Technology Assessment, 2011 Background: Rheumatoid arthritis (RA) is an inflammatory condition that typically causes a symmetrical chronic arthritis. Timely use of disease-modifying antirheumatic drugs (DMARDs) is an essential aspect of disease management, but many patients may not
K Malottki +10 more
doaj +1 more source
Disease-modifying antirheumatic drugs – Old and new: A brief overview
Clinical Dermatology Review, 2019 Rheumatological disorders comprise a vast subset of conditions with differing manifestations but overlap in pathogenesis. Disease-modifying antirheumatic drugs (DMARDs) are a diverse group of medications which aim at the various pathogenic factors ...
Vidya Divakar Baliga, Raghuveer S Prabhu
doaj +1 more source
Zero-shot Learning of Drug Response Prediction for Preclinical Drug Screening [PDF]
arXiv, 2023 Conventional deep learning methods typically employ supervised learning for drug response prediction (DRP). This entails dependence on labeled response data from drugs for model training. However, practical applications in the preclinical drug screening phase demand that DRP models predict responses for novel compounds, often with unknown drug ...
arxiv
Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents. A systematic review of randomized controlled trials [PDF]
, 2014 Objective. Treatment with tumour necrosis factor antagonists (anti-TNF) has been recognized as a risk factor for tuberculosis (TB) reactivation. Our aim was to evaluate risk of TB reactivation in rheumatologic and non-rheumatologic diseases treated with ...
Armuzzi, Alessandro +9 more
core +1 more source
Arthritis & Rheumatology, 2016 To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) in patients with active moderate‐to‐severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti–tumor ...
R. Fleischmann +9 more
semanticscholar +1 more source
Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis [PDF]
, 2019 Objective: To calculate the persistence, over a period of eight years, the retention rate of first and second-line of treatment with biological agents in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis and to compare ...
Balsa, Alejandro +5 more
core +3 more sources
Clinical connectivity map for drug repurposing: using laboratory tests to bridge drugs and diseases [PDF]
arXiv, 2020 Drug repurposing has attracted increasing attention from both the pharmaceutical industry and the research community. Many existing computational drug repurposing methods rely on preclinical data (e.g., chemical structures, drug targets), resulting in translational problems for clinical trials.
arxiv